{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:00:35Z","timestamp":1785265235408,"version":"3.55.0"},"reference-count":131,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["P30CA082709"],"award-info":[{"award-number":["P30CA082709"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Thymic epithelial tumors (TETs), which include thymomas and thymic carcinomas, are a rare, heterogeneous group of malignancies that originate from the thymus gland. As an important organ of immune cell development, thymic tumors, particularly thymomas, are often associated with paraneoplastic autoimmune disorders. The advances in targeted therapies for both solid and hematologic malignancies have resulted in improved patient outcomes, including better and more durable efficacy and improved toxicity. Targeted therapies have also been investigated in the treatment of TETs, though the results have largely been modest. These have included somatostatin-receptor-targeting therapies, KIT- and EGFR-directed tyrosine kinase inhibitors, epigenetic modulators, anti-angiogenesis agents, and agents targeting the cell proliferation and survival pathways and cell cycle regulators. Numerous investigated treatments have failed or underperformed due to a lack of a strong biomarker of efficacy. Ongoing trials are attempting to expand on previous experiences, including the exploration of effective drugs in early-stage disease. Novel combination therapy strategies are also undergoing evaluation, with the goal of augmenting efficacy and understanding the toxicity while expanding the biomarkers of efficacy and safety. With advances in technology to improve target identification and drug delivery, old targets may become new opportunities, and the subsequently developed drugs may find their place in the treatment of thymic tumors.<\/jats:p>","DOI":"10.3390\/cancers16020416","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T11:28:46Z","timestamp":1705577326000},"page":"416","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["What Have We Learned from Molecularly Informed Clinical Trials on Thymomas and Thymic Carcinomas\u2014Current Status and Future Directions?"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6089-2237","authenticated-orcid":false,"given":"Rohan","family":"Maniar","sequence":"first","affiliation":[{"name":"Division of Hematology & Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Sr.","given":"Patrick J.","family":"Loehrer","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"ref_1","first-page":"62","article-title":"New hope for cancer","volume":"157","author":"Lemonick","year":"2001","journal-title":"Time"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4137\/CMO.S6460","article-title":"Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations","volume":"6","author":"Jeyakumar","year":"2012","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_4","first-page":"100323","article-title":"Autoimmune Disease in Patients with Advanced Thymic Epithelial Tumors","volume":"3","author":"Singhal","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1097\/JTO.0000000000000295","article-title":"Approaching the patient with an anterior mediastinal mass: A guide for radiologists","volume":"9","author":"Carter","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The Integrated Genomic Landscape of Thymic Epithelial Tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.18632\/oncotarget.27978","article-title":"Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type","volume":"12","author":"Padda","year":"2021","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/oncolo\/oyac115","article-title":"Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers","volume":"27","author":"Girard","year":"2022","journal-title":"Oncologist"},{"key":"ref_9","first-page":"e2200465","article-title":"Clinicogenomic Landscape of Metastatic Thymic Epithelial Tumors","volume":"7","author":"Schneider","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/cncr.10374","article-title":"Somatostatin analogs and prednisone in advanced refractory thymic tumors","volume":"94","author":"Palmieri","year":"2002","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group Phase II Trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_12","unstructured":"Grupo Espanol de Tumores Neuroendocrinos (2023, November 01). Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05918302."},{"key":"ref_13","unstructured":"(2023, November 01). Vastra Gotaland Region; Advanced Accelerator Applications. 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04375267."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1200\/jco.2005.23.16_suppl.7068","article-title":"Phase II study of gefitinib treatment in advanced thymic malignancies","volume":"23","author":"Kurup","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"19087","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_16","unstructured":"Memorial Sloan Kettering Cancer Center, Eli Lilly and Company, M.D. Anderson Cancer Center, and City of Hope National Medical Center (2023, November 15). Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients with Locally Advanced or Recurrent Thymoma or Thymic Carcinoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01025089."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1200\/jco.2008.26.15_suppl.8116","article-title":"Imatinib for the treatment of thymic carcinoma","volume":"26","author":"Salter","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","article-title":"A phase I\/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: A clinical and translational study","volume":"20","author":"Thomas","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: An open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): A multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/cncr.33990","article-title":"Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy","volume":"128","author":"Perrino","year":"2022","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","article-title":"Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Conforti","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/j.cllc.2021.07.008","article-title":"PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients","volume":"23","author":"Remon","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"ref_26","unstructured":"Dwight, O., National Cancer Institute, and Ohio State University Comprehensive Cancer Center (2023, November 15). Pembrolizumab and Sunitinib Malate in Treating Participants with Refractory Metastatic or Unresectable Thymic Cancer, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03463460."},{"key":"ref_27","unstructured":"(2023, November 15). Phase I\/II Eval Safety & Prelim Activity Nivolumab Comb W\/Vorolanib Pts W\/Refractory Thoracic Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03583086."},{"key":"ref_28","unstructured":"(2023, November 15). Carboplatin and Paclitaxel with or Without Ramucirumab in Treating Patients with Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03694002."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: A multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II Study of Everolimus in Patients with Thymoma and Thymic Carcinoma Previously Treated with Cisplatin-Based Chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"891383","DOI":"10.3389\/fonc.2022.891383","article-title":"A phase II study of buparlisib in relapsed or refractory thymomas","volume":"12","author":"Radovich","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8519","DOI":"10.1200\/JCO.2018.36.15_suppl.8519","article-title":"Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients","volume":"36","author":"Besse","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e20578","DOI":"10.1200\/JCO.2018.36.15_suppl.e20578","article-title":"A phase 1b study of napabucasin (NAPA) + weekly paclitaxel (PTX) in patients (pts) with advanced thymoma and thymic carcinoma","volume":"36","author":"Kalra","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jtho.2022.10.008","article-title":"A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)","volume":"18","author":"Jung","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_35","unstructured":"VM Oncology, LLC (2023, November 15). Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03556228."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Priyadarshini, S., Allison, D.B., and Chauhan, A. (2022). Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071394"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/jcem.85.4.6547","article-title":"Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro","volume":"85","author":"Ferone","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","first-page":"634","article-title":"In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy","volume":"39","author":"Lastoria","year":"1998","journal-title":"J. Nucl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM199701233360405","article-title":"Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone","volume":"336","author":"Palmieri","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kirzinger, L., Boy, S., Marienhagen, J., Schuierer, G., Neu, R., Ried, M., Hofmann, H.S., Wiebe, K., Strobel, P., and May, C. (2016). Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168215"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1097\/RLU.0000000000000733","article-title":"Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT","volume":"40","author":"Makis","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_43","first-page":"S2066","article-title":"P1.17-015 Long Acting Octreotide plus Prednisone in Advanced Thymic Epithelial Tumors: A Real Life Clinical Experience","volume":"12","author":"Ottaviano","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.rpor.2020.08.012","article-title":"Octreotide in the treatment of malignant thymoma\u2013Case report","volume":"25","author":"Sorejs","year":"2020","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1097\/RLU.0000000000004553","article-title":"A Case of Metastatic Thymoma Responsive to Treatment with 177 Lu-DOTATATE","volume":"48","author":"Halperin","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/cac2.12005","article-title":"Spectrum of EGFR aberrations and potential clinical implications: Insights from integrative pan-cancer analysis","volume":"40","author":"Liu","year":"2020","journal-title":"Cancer Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.2005.04.8306","article-title":"Epidermal Growth Factor Receptor Biology in Head and Neck Cancer","volume":"24","author":"Kalyankrishna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.2147\/OTT.S111691","article-title":"Epidermal growth factor receptor and B7-H3 expression in esophageal squamous tissues correlate to patient prognosis","volume":"9","author":"Song","year":"2016","journal-title":"Onco Targets Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-008-0206-z","article-title":"Invasive ductal carcinoma of the breast with the \u201ctriple-negative\u201d phenotype: Prognostic implications of EGFR immunoreactivity","volume":"116","author":"Viale","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jcp.48.5.447","article-title":"Oncogene proteins and proliferation antigens in thymomas: Increased expression of epidermal growth factor receptor and Ki67 antigen","volume":"48","author":"Gilhus","year":"1995","journal-title":"J. Clin. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00194697","article-title":"Thymoma: Tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21","volume":"426","author":"Hayashi","year":"1995","journal-title":"Virchows Arch."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2559.1993.tb01181.x","article-title":"Expression of epidermal and nerve growth factor receptors in human thymus and thymomas","volume":"23","author":"Pescarmona","year":"1993","journal-title":"Histopathology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00432-001-0319-9","article-title":"Epidermal growth factor receptor expression in invasive thymoma","volume":"128","author":"Henley","year":"2002","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","article-title":"Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations","volume":"21","author":"Shah","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/cncr.20811","article-title":"Protein expression and gene amplification of epidermal growth factor receptor in thymomas","volume":"103","author":"Ionescu","year":"2005","journal-title":"Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma (391 views)","volume":"12","author":"Palmieri","year":"2007","journal-title":"Front. Biosci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Godesi, S., Lee, J., Nada, H., Quan, G., Elkamhawy, A., Choi, Y., and Lee, K. (2023). Small Molecule c-KIT Inhibitors for the Treatment of Gastrointestinal Stromal Tumors: A Review on Synthesis, Design Strategies, and Structure\u2014Activity Relationship (SAR). Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119450"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","article-title":"Gastrointestinal stromal tumors: Pathology and prognosis at different sites","volume":"23","author":"Miettinen","year":"2006","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/gcc.20503","article-title":"Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: Report of 220 tumors and review of literature","volume":"47","author":"Coffey","year":"2008","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/jid.2009.334","article-title":"KIT as a Therapeutic Target in Melanoma","volume":"130","author":"Garrido","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1378\/chest.128.1.140","article-title":"Immunohistochemical KIT (CD117) expression in thymic epithelial tumors","volume":"128","author":"Nakagawa","year":"2005","journal-title":"Chest"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/JTO.0b013e3181e96e30","article-title":"Expression and mutational status of c-kit in thymic epithelial tumors","volume":"5","author":"Petrini","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Strobel","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.lungcan.2008.03.035","article-title":"Absence of gene mutations in KIT-positive thymic epithelial tumors","volume":"62","author":"Tsuchida","year":"2008","journal-title":"Lung Cancer"},{"key":"ref_70","first-page":"18","article-title":"The epigenotype","volume":"1","author":"Waddington","year":"1942","journal-title":"Endeavour"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Psilopatis, I., Pergaris, A., Vrettou, K., Theocharis, S., and Troungos, C. (2022). Thymic Epithelial Neoplasms: Focusing on the Epigenetic Alterations. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23074045"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.semdp.2021.06.011","article-title":"Molecular landscape of thymic epithelial tumors","volume":"39","author":"Prays","year":"2022","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1038\/srep07336","article-title":"Mutations of epigenetic regulatory genes are common in thymic carcinomas","volume":"4","author":"Wang","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/2040620715592567","article-title":"Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: A perspective review","volume":"6","author":"Sawas","year":"2015","journal-title":"Ther. Adv. Hematol."},{"key":"ref_75","first-page":"7291","article-title":"Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA","volume":"63","author":"Kim","year":"2003","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lungcan.2014.04.008","article-title":"MicroRNA expression profiling of thymic epithelial tumors","volume":"85","author":"Ganci","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jneuroim.2015.08.013","article-title":"Aberrant decrease of microRNA19b regulates TSLP expression and contributes to Th17 cells development in myasthenia gravis related thymomas","volume":"288","author":"Wang","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","article-title":"T Helper Type 17 Cells Expand in Patients with Myasthenia-Associated Thymoma","volume":"76","author":"Wang","year":"2012","journal-title":"Scand. J. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"578129","DOI":"10.1016\/j.jneuroim.2023.578129","article-title":"Thymoma patients with or without myasthenia gravis have increased Th17 cells, IL-17 production and ICOS expression","volume":"381","author":"Cebi","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1067\/mtc.2002.124389","article-title":"Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors","volume":"124","author":"Tomita","year":"2002","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3892\/or.2010.861","article-title":"CD98 expression is associated with the grade of malignancy in thymic epithelial tumors","volume":"24","author":"Kaira","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","article-title":"Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus","volume":"190","author":"Cimpean","year":"2008","journal-title":"Ann. Anat."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.lungcan.2014.05.010","article-title":"Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: A tissue micro array-based multicenter study","volume":"85","author":"Lattanzio","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_84","first-page":"627","article-title":"Angiogenesis in the human thymoma assessed by subclassification of tumor-associated blood vessels and endothelial cells proliferation","volume":"51","author":"Raica","year":"2010","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2613.2011.00777.x","article-title":"Platelet-derived growth factor and platelet-derived growth factor receptor-\u03b1 expression in the normal human thymus and thymoma","volume":"92","author":"Cimpean","year":"2011","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long Lasting Response to the Multikinase Inhibitor Bay 43-9006 (Sorafenib) in a Heavily Pretreated Metastatic Thymic Carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience","volume":"103","author":"Bargou","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40644-019-0271-z","article-title":"RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study","volume":"19","author":"Lucidarme","year":"2019","journal-title":"Cancer Imaging"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41416-019-0558-7","article-title":"Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: Comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)","volume":"121","author":"Custodio","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1002\/cncr.27624","article-title":"Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy","volume":"118","author":"Stacchiotti","year":"2012","journal-title":"Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1158\/1535-7163.MCT-08-0715","article-title":"Combination of antiangiogenesis with chemotherapy for more effective cancer treatment","volume":"7","author":"Ma","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12964-022-00838-y","article-title":"Cancer combination therapies by angiogenesis inhibitors; a comprehensive review","volume":"20","author":"Ansari","year":"2022","journal-title":"Cell Commun. Signal"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/1759-7714.12891","article-title":"Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma","volume":"10","author":"Wang","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1016\/j.cllc.2018.06.005","article-title":"RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma\/B3 Thymoma with Area of Carcinoma","volume":"19","author":"Imbimbo","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti\u2013PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e21114","DOI":"10.1200\/JCO.2020.38.15_suppl.e21114","article-title":"Safety and activity of Combined AVElumab with Axitinib in unresectable or metastatic Thymomas B3 and Thymic carcinomas: The CAVEATT study","volume":"38","author":"Conforti","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2021.39.15_suppl.2578","article-title":"Phase I\/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts","volume":"39","author":"Wong","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/1078-0432.CCR-14-2518","article-title":"Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade","volume":"21","author":"Iams","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1002\/cncr.25367","article-title":"Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas","volume":"116","author":"Zucali","year":"2010","journal-title":"Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e3181e392a8","article-title":"Insulin-Like Growth Factor-1 Receptor Expression in Thymic Malignancies","volume":"5","author":"Girard","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","article-title":"Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors","volume":"13","author":"Haluska","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1517\/13543780903055049","article-title":"Cixutumumab","volume":"18","author":"McKian","year":"2009","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/bjc.2015.425","article-title":"A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas","volume":"114","author":"Radovich","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","article-title":"PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors","volume":"11","author":"Alberobello","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Maury, J.-M., Merveilleux du Vignaux, C., Drevet, G., Zarza, V., Chalabreysse, L., Maisse, C., Gineys, B., Dolmazon, C., Tronc, F., and Girard, N. (2019). Activation of the mTOR\/ Akt pathway in thymic epithelial cells derived from thymomas. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0197655"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1158\/1078-0432.CCR-09-0594","article-title":"Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers","volume":"15","author":"Girard","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/JTO.0000000000000298","article-title":"State of the art of genetic alterations in thymic epithelial tumors","volume":"9","author":"Rajan","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0002-9440(10)64426-4","article-title":"Chromosome 6 suffers frequent and multiple aberrations in thymoma","volume":"161","author":"Inoue","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1158\/1078-0432.CCR-12-3260","article-title":"Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors","volume":"19","author":"Petrini","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_116","first-page":"1601","article-title":"Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: Possibly four regions of deletion","volume":"2","author":"Noviello","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"ref_117","first-page":"677","article-title":"A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer","volume":"13","author":"Theile","year":"1996","journal-title":"Oncogene"},{"key":"ref_118","first-page":"2170","article-title":"Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization","volume":"58","author":"Bastian","year":"1998","journal-title":"Cancer Res."},{"key":"ref_119","first-page":"313","article-title":"Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma","volume":"42","author":"Aalto","year":"2001","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<639::AID-IJC5>3.0.CO;2-Y","article-title":"p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma","volume":"73","author":"Hirabayashi","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1038\/cddis.2012.92","article-title":"Copy number aberrations of BCL2 and CDKN2A\/B identified by array-CGH in thymic epithelial tumors","volume":"3","author":"Petrini","year":"2012","journal-title":"Cell Death Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2017.01.028","article-title":"Loss of p16(INK4A) Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas","volume":"12","author":"Aesif","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"viii5","DOI":"10.1093\/annonc\/mdz383","article-title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","volume":"30","author":"Amatu","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejcts.2005.06.034","article-title":"Expression of neurotrophin receptors in surgically resected thymic epithelial tumors","volume":"28","author":"Kim","year":"2005","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.21873\/anticanres.15868","article-title":"Tropomyosin-related Kinase B Is Potentially a Biomarker of Prognosis and Therapeutic Target for Malignant Thymic Epithelial Tumors","volume":"42","author":"Ozono","year":"2022","journal-title":"Anticancer. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s10637-011-9774-6","article-title":"Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies","volume":"30","author":"Weiss","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1158\/0008-5472.CAN-17-1323","article-title":"Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors","volume":"77","author":"Conforti","year":"2017","journal-title":"Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors","volume":"34","author":"Gabrail","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in Cancer Immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1749-8090-8-92","article-title":"STAT3 expression correlates with prognosis of thymic epithelial tumors","volume":"8","author":"Li","year":"2013","journal-title":"J. Cardiothorac. Surg."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1007\/s11748-021-01655-9","article-title":"STAT3 activation in thymic epithelial tumors: Correlation with cyclin D1, JAK3, and clinical behavior","volume":"69","author":"Okabe","year":"2021","journal-title":"Gen. General. Thorac. Cardiovasc. Surg."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/416\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:49:55Z","timestamp":1760104195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":131,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16020416"],"URL":"https:\/\/doi.org\/10.3390\/cancers16020416","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}